Artrya

PREDICTING if someone is at imminent risk of a heart attack has been for a long time the Holy Grail for heart researchers. WA start-up Artrya Pty Ltd is now applying Artificial Intelligence to the challenge. 

Several exciting AI innovations are emerging from WA, and the world is watching.

A local medtech focused on the early detection of heart disease has sought $40 million through an IPO, which will in part be used to fund the development and commercialisation of its software.

Crawley-based Artrya has been shortlisted as a preferred supplier of AI software by the UK Health Service for its heart disease detection program.

Local medtech Artrya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.

WA’s health budget has tripled during the past 15 years, but there are concerns about patient outcomes amid workforce, bureaucracy and governance pressures.

Artrya shares continued to drop this morning after the US Food and Drug Administration knocked back its AI-based coronary diagnostic product for commercial use.

A Perth-based artificial intelligence healthcare company has appointed a US health technology expert to its board.

Artrya’s coronary diagnostic product has been given regulatory approval for use in the UK after being knocked back by the US Food and Drug Administration five months ago.

Limitless: Having taken its AI technology to an IPO, Artrya is working to overcome regulatory hurdles.

Mark Pownall and Mark Beyer discuss Mark McGowan's cabinet reshuffle, Clough, gas shortages, Genesis Minerals and St Barbara, CBH Group, the year in markets, HealthEngine, Artrya and the SKA.

Medical technology company Artrya Limited has appointed experienced executive Mathew Regan as the company’s new leader after its co-founder John Barrington resigned.

West Perth medtech Artrya has signed a three-year deal to advance the screening and diagnosis of heart disease in Australia.